News - Licensing, Pharmaceutical

Filter

Current filters:

LicensingPharmaceutical

Popular Filters

1 to 25 of 749 results

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

08-07-2014

Chinese drugmaker Yabao Pharmaceutical has entered a strategic partnership with US pharma major Eli Lilly…

ChinaDiabetesEli LillyLicensingPharmaceuticalYabao Pharmaceutical

UCB and Dermira link up for Cimzia in dermatology

UCB and Dermira link up for Cimzia in dermatology

03-07-2014

Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered…

CanadaCimziaDermatologicalsDermiraEuropeLicensingPharmaceuticalResearchUCBUSA

Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

02-07-2014

Ireland-headquartered drugmaker Jazz Pharmaceuticals has signed a definitive agreement Pharmaceuticals…

defibrotideGentiumJazz PharmaceuticalsLicensingNephrology and HepatologyNorth AmericaPharmaceuticalSigma-TauSouth America

CureVac in deal with Sanofi Pasteur for mRNA-based prophylactic vaccine

01-07-2014

German clinical-stage biopharma company CureVac has entered into an exclusive license agreement with…

LicensingPharmaceuticalSanofiSanofi PasteurVaccines

Boston Strategics in-licenses Eisai’s cancer candidate E6201

01-07-2014

US clinical-stage drug R&D company Boston Strategics Corp has entered into an exclusive licensing and…

Boston Strategics CorpE6201EisaiLicensingOncologyPharmaceutical

Helsinn out-licenses potential NSCLC drug in Turkey

Helsinn out-licenses potential NSCLC drug in Turkey

30-06-2014

Privately-held Swiss pharma group Helsinn said today that rights to anamorelin, its innovative ghrelin…

GEN IlacHelsinnLicensingOncologyPharmaceuticalTurkey

Vectura signs additional deal with unnamed US pharma company

Vectura signs additional deal with unnamed US pharma company

30-06-2014

UK developer of inhaled therapies Vectura Group has signed a US collaboration, development and license…

LicensingPharmaceuticalRespiratory and PulmonaryUKUSAVecturaVR315

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

26-06-2014

Japanese firm Teijin has entered into an agreement with the UK subsidiary of privately-owned Italian…

EZN-2279ImmunologicalsJapanLicensingPharmaceuticalSigma-TauTeijin

BioAlliance Pharma signs deal with EMS for Sitavig in Brazil

BioAlliance Pharma signs deal with EMS for Sitavig in Brazil

26-06-2014

French oncology specialist BioAlliance Pharma SA has announced a license agreement for Sitavig (acyclovir…

Antibiotics and Infectious diseasesBioAlliance PharmaBrazilLicensingPharmaceuticalSitavig

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

24-06-2014

US drugmaker Ligand Pharmaceuticals has signed an exclusive global license accord with TG Therapeutics…

ImmunologicalsLicensingLigand PharmaceuticalsOncologyPharmaceuticalTG Therapeutics

Sanofi returns rights for cancer candidate MM-121 to Merrimack

Sanofi returns rights for cancer candidate MM-121 to Merrimack

20-06-2014

USA-based Merrimack Pharmaceuticals says it has reached an agreement with French drug major Sanofi to…

LicensingMerrimack PharmaceuticalsMM-121OncologyPharmaceuticalSanofi

Pfizer inks multi-million $ cancer immunology deal with Cellectis

Pfizer inks multi-million $ cancer immunology deal with Cellectis

18-06-2014

France-based genome engineering specialist Cellectis saw its shares rocket nearly 50% to 9.26 euros,…

CellectisLicensingMergers & AcquisitionsOncologyPfizerPharmaceutical

MRC Technology sells its melanocortin receptors program to Pfizer

MRC Technology sells its melanocortin receptors program to Pfizer

18-06-2014

UK-based technology transfer organization MRC Technology has sold its melanocortin receptors (MCRs) program,…

LicensingMRC TechnologyPfizerPharmaceutical

Merck & Co returns rights to Endocyte’s vintafolide

Merck & Co returns rights to Endocyte’s vintafolide

18-06-2014

Shares of USA-based Endocyte fell 19.7% to $6.20 in after-hours trading yesterday, after the company…

CisplatinEnd point of clinical trialsEndocyteHealth Medical PharmaLicensingMerck & CoOncologyPEGylationPharmaceuticalPlatinum-resistant ovarian cancervintafolide

Merck pulls out of license deal with Ono Pharma for MS drug ceralifimod

Merck pulls out of license deal with Ono Pharma for MS drug ceralifimod

17-06-2014

German drug major Merck KGaA revealed this morning that, by mutual agreement, it has terminated its licensing…

ceralifimodLicensingMerck KGaAMerck SeronoNeurologicalOno PharmaceuticalPharmaceutical

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

12-06-2014

Anglo-Swedish pharma major AstraZeneca has signed a global licence accord with Synairgen, an AIM-listed…

AstraZenecaChronic lower respiratory diseasesHealth Medical PharmaLicensingMajorMedicinePharmaceuticalPulmonologyRespiratory and PulmonarySNG001Synairgen

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

11-06-2014

Privately-held California, USA-based specialty vaccine firm PaxVax has entered into a research and development…

Anti-viralsLicensingPaxVaxPharmaceuticalResearchVaccines

Chiesi links with UCL to test a novel therapeutic for birth asphyxia

Chiesi links with UCL to test a novel therapeutic for birth asphyxia

10-06-2014

Privately-held Italian drugmaker Chiesi Farmaceutici has entered into a collaboration with University…

Chiesi FarmaceuticiLicensingmelatoninNeurologicalPharmaceuticalResearch

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

02-06-2014

Finland-based drugmaker Orion Corp has entered into a global partnership with German pharma major Bayer…

BayerGlobalLicensingODM-201OncologyOrion CorpPharmaceuticalResearch

Richter and HRA Pharma in deal on Esmya for Latin America

30-05-2014

Hungary’s largest drugmaker Gedeon Richter and France-based Laboratoire HRA Pharma have concluded a…

EsmyaGedeon RichterHRA PharmaLicensingPharmaceuticalSouth AmericaWomen's Health

Retrophin acquires US Thiola rights from Mission Pharmacal

Retrophin acquires US Thiola rights from Mission Pharmacal

30-05-2014

US drugmaker Retrophin has entered into a license agreement with Mission Pharmacal, a private company…

LicensingMission PharmacalNephrology and HepatologyPharmaceuticalRare diseasesRetrophinThiolaUSA

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

28-05-2014

Japanese drug majors Dainippon Sumitomo Pharma and Daiichi Sankyo have entered into a license agreement…

ArgentinaBrazilDaiichi SankyoDainippon Sumitomo PharmaLicensinglurasidoneNeurologicalPharmaceuticalSouth AmericaVenezuela

Abiogen Pharma out-licenses rights to market Attila in China and nearby territories to Lee’s Pharma

Abiogen Pharma out-licenses rights to market Attila in China and nearby territories to Lee’s Pharma

28-05-2014

Italian drugmaker Abiogen Pharma has signed a license, distribution and supply agreement with Hong Kong-based…

Abiogen PharmaAsia-PacificAttilaChinaLee's PharmaceuticalLicensingPharmaceuticalRare diseases

1 to 25 of 749 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top